LOS ALTOS, Calif., Oct. 17, 2016 /PRNewswire/ -- Globavir
Biosciences, Inc., a biotechnology company that develops
therapeutics for infectious diseases and oncology, and diagnostics
for infectious diseases, announced a partnership with Bio-Rad
Laboratories, Inc., a global provider of life science research and
clinical diagnostics products. Under the terms of the agreement,
Bio-Rad will license Globavir's PanGlob™ dengue detection
technology for use in an assay that includes dengue virus
detection. Financial terms of the agreement were not
disclosed.
The PanGlob assay, originally developed by Stanford University researchers, includes improved
diagnostic sensitivity, efficacy across all four dengue serotypes,
and enhanced specificity for dengue over related viruses. This
advanced technology reduces the risk of incorrect results.
"Infectious disease outbreaks are a threat to human health with
the potential of quickly reaching an epidemic level," said Globavir
CEO Dr. Shalabh Gupta. "Correct
diagnosis of these types of diseases is the crucial first step
toward effective patient care and surveillance. Globavir is excited
to lend our dengue technology toward the creation of this important
assay."
"Bio-Rad is pleased to partner with Globavir for a dengue assay
that provides improved sensitivity and specificity in detecting
this virus," said Bio-Rad President Clinical Diagnostics Group John
Hertia.
About Dengue
Dengue is a mosquito-borne viral infection that causes flu-like
illness that can develop into a potentially lethal complication
called severe dengue. According to the World Health Organization,
the global incidence of dengue has grown dramatically in recent
decades, with about half of the world's population now at risk.
Driven by increased travel of asymptomatic patients and the global
spread of the disease-carrying mosquito, a recent estimate reports
that dengue infection affects approximately 390 million patients
worldwide, with nearly 100 million of these cases manifesting with
consequences ranging from the painful and debilitating dengue fever
to severe dengue. Dengue is endemic in more than 100 countries in
the WHO regions of Africa, the
Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific.
Although there is no specific treatment for dengue or severe
dengue, early detection and access to proper medical care lowers
fatality rates below one percent.
About Globavir
Globavir Biosciences is a biotechnology company developing
life-saving technologies for treatment of oncology and infectious
diseases. Globavir is developing powerful combination drug
therapies and diagnostic tests for the treatment of dengue fever.
Globavir, based in Los Altos,
California, USA, has rights to develop and commercialize a
dengue diagnostic test platform developed at Stanford University. Globavir's diagnostic kits
have received CE-mark approval and are currently being marketed
globally. The company has the leading molecular diagnostic test to
detect dengue infection as well as a platform for other virus
detection tests. Additionally, Globavir has multiple oncology drugs
in development.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than
100,000 research and healthcare industry customers through its
global network of operations. The company employs approximately
8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please
visit www.bio-rad.com
Logo - http://photos.prnewswire.com/prnh/20140818/137091
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/globavir-announces-licensing-agreement-with-bio-rad-for-globavirs-dengue-detection-technology-300345449.html
SOURCE Globavir Biosciences, Inc.